Processa Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Related Party Transactions (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	Oct. 04, 2017
Reimbursement amount	$ 1,025	$ 0	$ 28,505	$ 49,089
Reimbursement amount	$ 94,766		$ 94,766		$ 62,709
Senior Convertible Notes [Member] \| Chairman of the Board of Directors [Member]
Shares purchased in private placement transaction	132,160		132,160
Number of common stock and warrants to purchase shares	103,117		103,117
Convertible debt	$ 200,000		$ 200,000
Senior Convertible Notes [Member] \| Chief Executive Officer [Member]
Shares purchased in private placement transaction	132,160		132,160
Number of common stock and warrants to purchase shares	103,117		103,117
Convertible debt	$ 200,000		$ 200,000
Corlyst [Member]
Reimbursement amount	$ 79,422		$ 79,422		$ 62,709
Shares purchased in private placement transaction	132,159		132,159
Funds [Member] \| Senior Convertible Notes [Member]
Number of common stock and warrants to purchase shares	515,583		515,583			515,583
Convertible debt	$ 566,639		$ 566,639			$ 1,000,000